Q-omics provides the consensus-scored METTL15 profile across patient tissues and cancer cell-line models. METTL15 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, METTL15 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, METTL15 RNA expression shows 20,860 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where METTL15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL15 survival associations across molecular data types. METTL15 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL15 RNA expression–survival associations across cancer types. High METTL15 expression shows unfavorable associations in PAAD, CESC, KICH and LIHC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for METTL15 RNA expression.
This table summarizes METTL15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for METTL15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL15 shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, KIRC, STAD and BRCA. The THCA box plot shows higher METTL15 RNA expression in normal versus tumor tissue (log2 FC = −0.424, t-test p < 0.001).
This table shows molecular features associated with METTL15 in patient tissues and cancer cell lines. In patient samples, METTL15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
